MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma.
about
Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine TrialsClinical, pathological, and molecular data on desmoplastic/nodular medulloblastoma: case studies and a review of the literature.Cytogenetic prognostication within medulloblastoma subgroups.Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial.Oncologic Phenotype of Peripheral Neuroblastic Tumors Associated With PHOX2B Non-Polyalanine Repeat Expansion Mutations.Fanconi anemia and solid malignancies in childhood: a national retrospective study.
P2860
MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma.
@en
MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma.
@nl
type
label
MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma.
@en
MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma.
@nl
prefLabel
MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma.
@en
MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma.
@nl
P2093
P50
P1433
P1476
MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma.
@en
P2093
Alexandre Vasiljevic
Annie Laquerriere
Camille Grison
Catherine Miquel
Gaelle Pierron
Jérôme Couturier
Sophie Michalak
P304
P356
10.1016/J.CANCERGEN.2013.02.003
P50
P577
2013-04-08T00:00:00Z